首页> 外文期刊>International Urology and Nephrology >T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy.
【24h】

T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy.

机译:T1G3高危NMIBC(非肌肉浸润性膀胱癌):保守治疗与立即膀胱切除术比较。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The management of stage T1 poorly differentiated G3 bladder cancer invading the lamina propria continues to be debated. These tumours are associated with a high risk of recurrence and progression; concomitant carcinoma in situ and/or multifocality are negative prognostic factors. Choosing between a preserving approach such as trans-urethral resection of the bladder (TURB) followed by maintenance bacillus Calmette-Guerin (BCG) and an invasive approach like cystectomy is critical. PATIENTS AND METHODS: Overall, 80 patients underwent TURB and RE-TURB followed by intra-vesical induction treatment with BCG plus maintenance (Group A) while 72 patients underwent immediate radical cystectomy with extended lymphadenectomy (Group B). Patients were divided into 3 subgroups: uni-focal tumours, multi-focal tumours and carcinoma in situ associated lesions. In Group A, time to first recurrence and time to progression were analysed. A comparison was made between Group A and Group B regarding progression-free survival, cancer-specific survival and overall survival with a median follow-up time of 8.3 years. RESULTS: As far as concerns Group A patients, 42 recurrences (52.5%) were reported in a median time of 10.4 months (range 3-26) and 25 progressions (31.2%) in a median time of 25 months (range 3-68). As far as concerns time to first recurrence and time to progression, both the Kaplan-Meier survival curves obtained are significant and P values are, respectively, 0.0263 and 0.0011. Comparing Groups A and B patients, 25 progressions (31.2%) in a median time of 25 months (range 3-68) and 18 progressions (25%) in a median time of 25.9 months (range 4-72), respectively, were recorded. Regarding overall survival, at 10 years, 24 deaths (42.5%) occurred in a median time of 55.4 months (range 12-94) in Group A and 42 deaths (58.3%) in a median time of 54.9 months (10-100) in Group B. Cancer-specific survival was evaluated in Group A with a total of 18 deaths (22.5%) in a median time of 47.5 months (range 16-78), and in Group B with a total of 16 deaths (22.2%) in a median time of 45.7 months (range 16-88). The progression-free survival Kaplan-Meier curve is not significant, the P value being 0.3801; the overall survival curve is significant with a P value of 0.0487 while the cancer-specific survival curve is not significant with a P value of 0.9762. DISCUSSION: In Group A, considering "time to first recurrence", the difference is greater between unifocal lesions and multifocal or Cis-associated lesions. Conversely, for "time to progression", there is a greater difference between unifocal and multifocal tumours and Cis-associated tumours. Looking at progression-free survival statistically significant difference, like in cancer-specific survival. A statistically significant difference was observed in overall survival being in favour of conservative treatment thus reflecting that conservative treatment is not burdened by all the surgical and post-operative complications of cystectomy. CONCLUSIONS: Although NMIBC invading the lamina propria, stage G3, with or without Cis-associated lesions are burdened both by a high volume of recurrences and progressions, cystectomy could be considered an aggressive approach. New biological markers are now needed which are able to predict the behaviour of the cancer and to guide the decision-making process between conservative or aggressive treatment.
机译:背景:侵袭固有层的T1期低分化G3膀胱癌的治疗仍在争论。这些肿瘤与复发和进展的高风险有关。伴随原位癌和/或多灶性是阴性预后因素。在保留方法(如经尿道膀胱尿道切除术(TURB),继而维持卡介苗-卡林芽孢杆菌(BCG)进行维护)与侵入性方法(如膀胱切除术)之间进行选择至关重要。患者与方法:总体上,80例患者接受了TURB和RE-TURB,然后进行了BCG加维持的膀胱内诱导治疗(A组),而72例患者接受了彻底根治性膀胱切除术并进行了广泛的淋巴结清扫术(B组)。患者分为三个亚组:单灶性肿瘤,多灶性肿瘤和原位癌相关病变。在A组中,分析了首次复发的时间和进展的时间。 A组和B组在无进展生存期,癌症特异性生存期和总生存期方面进行了比较,平均随访时间为8.3年。结果:就A组患者而言,报告的中位时间为10.4个月(范围3-26)中有42例复发(52.5%),而在25个月的中位时间(3-68中)中有25例复发(31.2%)。 )。就首次复发时间和进展时间而言,获得的Kaplan-Meier生存曲线均很显着,P值分别为0.0263和0.0011。比较A组和B组患者,中位时间为25个月(范围3-68)为25个进展(31.2%),中位时间为25.9个月(范围4-72)为18个进展(25%)。记录下来。关于整体生存,在10年时,A组的中位时间为55.4个月(范围12-94),有24例死亡(42.5%),中位时间为54.9个月(10-100),有42例死亡(58.3%)。在B组中,在47.5个月的中位时间(范围16-78)中,共有18例死亡(22.5%)被评估为A组的癌症特异性生存,而在B组中,共有16例死亡(22.2%)被评估为癌症的生存率。 )的平均时间为45.7个月(范围16-88)。无进展生存期Kaplan-Meier曲线不显着,P值为0.3801。总生存曲线的显着性为P值0.0487,而癌症特异性生存曲线的显着性P值为0.9762。讨论:在A组中,考虑到“首次复发时间”,单灶性病变与多灶性或顺式相关病变之间的差异更大。相反,对于“进展时间”,单灶性和多灶性肿瘤与顺式相关肿瘤之间的差异更大。查看无进展生存期具有统计学上的显着差异,例如特定于癌症的生存期。在总体生存率上观察到统计学上的显着差异,赞成采用保守治疗,从而反映出保守治疗并不受膀胱切除术的所有手术和术后并发症的负担。结论:尽管NMIBC侵犯固有层,G3期,无论是否伴有Cis相关病变,均会因大量复发和进展而加重负担,但膀胱切除术仍被认为是一种积极的方法。现在需要新的生物标记物,它们能够预测癌症的行为并指导保守治疗或积极治疗之间的决策过程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号